1. Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases
   Si Shi et al, 2018, World Journal of Gastroenterology CrossRef
2. Carbohydrate antigen 19‑9 as a prognostic biomarker in pancreatic neuroendocrine tumors
   Guopei Luo et al, 2017, Oncology Letters CrossRef
3. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)
   Wenming Wu et al, 2021, Journal of Pancreatology CrossRef
4. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
   Feng Yin et al, 2022, World Journal of Gastroenterology CrossRef
5. Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms
   Feng Jiao et al, 2023, Chinese Medical Journal CrossRef
6. The side effects and complications of percutaneous iodine-125 seeds implantation under CT-guide for patients with advanced pancreatic cancer
   Wei-Fu Lv et al, 2017, Medicine CrossRef
7. Treatment options for PNET liver metastases: a systematic review
   Giuseppe Nigri et al, 2018, World Journal of Surgical Oncology CrossRef
8. Surgical management for pancreatic neuroendocrine neoplasms with synchronous hepatic metastases: A literature review
   Bohui Yin et al, 2022, Surgery in Practice and Science CrossRef
9. Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma
   Jianwei Zhang et al, 2022, Neuroendocrinology CrossRef
10. Liver metastases
    Diamantis I. Tsilimigras et al, 2021, Nature Reviews Disease Primers CrossRef
11. Decreasing utilization of surgical interventions amongst patients with pancreatic neuroendocrine tumor with liver metastases
    Neda Amini et al, 2024, The American Journal of Surgery CrossRef
12. Synchronous primary duodenal papillary adenocarcinoma and gallbladder carcinoma: A case report and review of literature
    Jing Chen et al, 2022, World Journal of Clinical Cases CrossRef
13. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Jun-Xi Xiang et al, 2018, Annals of Surgical Oncology CrossRef
14. Pancreatic neuroendocrine tumors
    Jian Sun, 2017, Intractable & Rare Diseases Research CrossRef
15. A modified M-stage classification based on the metastatic patterns of pancreatic neuroendocrine neoplasms: a population-based study
    Xianbin Zhang et al, 2018, BMC Endocrine Disorders CrossRef
16. Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis
    Thomas M. Pausch et al, 2021, Cancers CrossRef
17. Advances in the treatment of gastroenteropancreatic neuroendocrine neoplasms with somatostatin analogs
    Ming Lu et al, 2023, Journal of Pancreatology CrossRef
18. Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER‐based analysis of 15,836 cases
    Ningzhen Fu et al, 2021, Cancer Medicine CrossRef
19. Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival
    Shinsei Yumoto et al, 2022, Clinical Journal of Gastroenterology CrossRef
20. Surgical management of pancreatic neuroendocrine neoplasms
    Piero Alberti et al, 2023, Laparoscopic, Endoscopic and Robotic Surgery CrossRef
21. A radiomics-based interpretable model to predict the pathological grade of pancreatic neuroendocrine tumors
    Jing-Yuan Ye et al, 2023, European Radiology CrossRef